Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2024)

Barinthus Biotherapeutics has reported Revenue for 5 years, with the latest figure at $15.0 million in Q3 2024.

• For the quarter ending Q3 2024, Revenue changed N/A year-over-year to $15.0 million; the trailing twelve-month figure through Dec 2025 stood at $15.0 million (changed 0.0% YoY), and the FY2024 full-year result was $15.0 million, up 1766.46% from the prior year.
• Revenue for Q3 2024 stood at $15.0 million, up from $334000.0 in the prior quarter.
• The five-year high for Revenue was $17.1 million in Q2 2022, with the low at -$1000.0 in Q4 2021.
• Historically, Revenue has averaged $4.4 million across 5 years, with a median of $511000.0 in 2020.
• Annual changes were most pronounced in 2021 — Revenue slumped 100.28% — and 2022, when it jumped 645800.0%.
• Barinthus Biotherapeutics' Revenue stood at $354000.0 in 2020, then tumbled by 100.28% to -$1000.0 in 2021, then jumped by 645800.0% to $6.5 million in 2022, then sank by 94.83% to $334000.0 in 2023, then soared by 4381.74% to $15.0 million in 2024.
• The last three Revenue figures came in at $15.0 million (Q3 2024), $334000.0 (Q2 2023), and $468000.0 (Q1 2023), per Business Quant data.